Browse All

Current Filters

CLEAR FILTER x

TITLE

Immunoglobulin Level Changes in Patients with Multiple Sclerosis Treated with Anti-CD20 Monoclonal Antibodies

Author:Vollmer, Brandi   Bourassa, Timber   Marsh, Erin   Dao, Vi   Gadkari, Abhijit   Brown, Brandon   Sillau, Stefan   Nair, Kavita   Alvarez, Enrique   

Session Name:P9: Multiple Sclerosis: Clinical Trials and Therapeutics (including Safety) 2  

Topic:Multiple Sclerosis  

Program Number:P9.011  

Author Institution:University of Colorado, Aurora, CO  Novartis, East Hanover, NJ  

The Safety Profile of Fenebrutinib in Patients with Multiple Sclerosis Is Consistent with Those in Previously Studied Autoimmune Indications

Author:Oh, Jiwon   Raievska, Anastasiia   Sierzega, Malgorzata   Cerqueira, João   Riley, Claire S.   Caunt, Maresa   Ratchford, John N.   Goodyear, Alexandra   Vanevski, Konstantina   Sormani, Maria Pia   Giovannoni, Gavin   

Session Name:P9: Multiple Sclerosis: Clinical Trials and Therapeutics (including Safety) 2  

Topic:Multiple Sclerosis  

Program Number:P9.012  

Author Institution:St. Michael's Hospital, University of Toronto, Toronto, ON, Canada  F. Hoffmann-La Roche Ltd, Basel, Switzerland  University of Minho, Braga, Portugal  Columbia University Medical Center, New York, NY  Genentech Inc., South San Francisco, CA  University of Genoa, Genoa, Italy  Blizard University, Queen Mary University of London, London, United Kingdom  

Changes in Plasma NfL and GFAP in Response to Anti-CD20 Treatment in MS

Author:Gross, Robert   Selva, Sean   Ritchie, Alanna   Sillau, Stefan   

Session Name:P9: Multiple Sclerosis: Clinical Trials and Therapeutics (including Safety) 2  

Topic:Multiple Sclerosis  

Program Number:P9.013  

Author Institution:University of Colorado, Aurora, CO  

Real-world Effectiveness, Tolerability, and Safety of Ofatumumab at 12-month Follow-up

Author:Hersh, Carrie   Amin, Moein   Harvey, Tucker   Moss, Brandon   Tai, Ming-Hui   Gadkari, Abhijit   Brown, Brandon   Conway, Devon   

Session Name:P9: Multiple Sclerosis: Clinical Trials and Therapeutics (including Safety) 2  

Topic:Multiple Sclerosis  

Program Number:P9.014  

Author Institution:Lou Ruvo Center for Brain Health, Cleveland Clinic, Las Vegas, NV  Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, OH  Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH  Novartis Pharmaceuticals Corporation, East Hanover, NJ  

Phase ? Clinical Trial of NKT Cell-targeting Glycolipid OCH-NCNP1 for Patients with Relapsing Multiple Sclerosis

Author:Okamoto, Tomoko   Sato, Wakiro   Lin, Youwei   Kimura, Yukio   Sato, Noriko   Shimizu, Yuko   Nishida, Yoichiro   Yokota, Takanori   Taketsuna, Masanori   Okada, Yu   Ishizuka, Takami   Nakamura, Harumasa   Miyake, Sachiko   Takahashi, Yuji   Yamamura, Takashi   

Session Name:P9: Multiple Sclerosis: Clinical Trials and Therapeutics (including Safety) 2  

Topic:Multiple Sclerosis  

Program Number:P9.015  

Author Institution:National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan  National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan  Tokyo Women's Medical University School of Medicine, Tokyo, Japan  Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan  Translational Research Center for Medical Innovation, Foundation for Biomedical Research and Innovation at Kobe, Hyogo, Japan  Clinical Research & Education Promotion Division, National Center Hospital, National Center of Neurology and Psychiatry, Tokyo, Japan  Juntendo University Graduate School of Medicine, Tokyo, Japan